Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31075302 | 0.92 | TDP1 (0.40) | TDP1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL29903714 | 0.88 | TDP1 (0.39) | TDP1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL15920997 | 0.84 | TDP1 (0.38) | TDP1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL1771995 | 0.83 | TDP1 (0.41) | TDP1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL19465643 | 0.83 | ALDH1A1 (0.39) | MEN1KMT2APOLBALDH1A1L3MBTL1 | |
| SCHEMBL7220622 | 0.81 | POLB (0.38) | TDP1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL4613905 | 0.81 | TDP1 (0.50) | TDP1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL5356481 | 0.80 | TDP1 (0.45) | TDP1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL6848284 | 0.80 | TDP1 (0.45) | TDP1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL20473354 | 0.80 | ALDH1A1 (0.40) | TDP1MEN1KMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042372-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | Montell Technology Company bv (NL) | 2000-10-11 | — | — | EP | claimed |
| WO-2000026259-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | MONTELL TECHNOLOGY COMPANY BV (NL) | 2000-05-11 | — | — | WO | claimed |
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024177984-A1 | BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4298092-A1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| EP-1042372-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | Montell Technology Company bv (NL) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000026259-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | MONTELL TECHNOLOGY COMPANY BV (NL) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | GPR17, GPR27, GPR119 | TDP1 3673/4885MEN1 2067/4885KMT2A 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.